KR20200054171A - 경피 칸나비디올 겔을 이용한 골관절염의 치료 방법 - Google Patents

경피 칸나비디올 겔을 이용한 골관절염의 치료 방법 Download PDF

Info

Publication number
KR20200054171A
KR20200054171A KR1020207005446A KR20207005446A KR20200054171A KR 20200054171 A KR20200054171 A KR 20200054171A KR 1020207005446 A KR1020207005446 A KR 1020207005446A KR 20207005446 A KR20207005446 A KR 20207005446A KR 20200054171 A KR20200054171 A KR 20200054171A
Authority
KR
South Korea
Prior art keywords
cbd
osteoarthritis
cannabidiol
pain
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207005446A
Other languages
English (en)
Korean (ko)
Inventor
테드 스미스
제임스 그리서
낸시 티치
존 메센하이머
도나 거터만
다니엘 클로
Original Assignee
지네르바 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지네르바 파마슈티컬스, 인코포레이티드 filed Critical 지네르바 파마슈티컬스, 인코포레이티드
Publication of KR20200054171A publication Critical patent/KR20200054171A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020207005446A 2017-08-14 2018-08-13 경피 칸나비디올 겔을 이용한 골관절염의 치료 방법 Ceased KR20200054171A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762545468P 2017-08-14 2017-08-14
US62/545,468 2017-08-14
US201862661733P 2018-04-24 2018-04-24
US62/661,733 2018-04-24
PCT/IB2018/056090 WO2019034985A1 (en) 2017-08-14 2018-08-13 METHODS OF TREATING ARTHROSIS USING CANNABIDIOL TRANSDERMAL GEL

Publications (1)

Publication Number Publication Date
KR20200054171A true KR20200054171A (ko) 2020-05-19

Family

ID=65362584

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207005446A Ceased KR20200054171A (ko) 2017-08-14 2018-08-13 경피 칸나비디올 겔을 이용한 골관절염의 치료 방법

Country Status (11)

Country Link
US (4) US20200170963A1 (enExample)
EP (1) EP3668500A4 (enExample)
JP (3) JP2020530857A (enExample)
KR (1) KR20200054171A (enExample)
AU (2) AU2018318425A1 (enExample)
BR (1) BR112020003025A2 (enExample)
CA (1) CA3072849A1 (enExample)
IL (2) IL301622A (enExample)
JO (1) JOP20200031A1 (enExample)
MX (1) MX2020001768A (enExample)
WO (1) WO2019034985A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024085581A1 (ko) * 2022-10-17 2024-04-25 (주)인벤티지랩 염증성 질환의 치료 또는 예방을 위한 서방형 주사용 조성물 및 이의 제조 방법

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530857A (ja) * 2017-08-14 2020-10-29 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 経皮カンナビジオールゲルを用いた変形性関節症の治療方法
US12582664B2 (en) 2017-09-28 2026-03-24 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
CA3300266A1 (en) 2017-09-28 2026-03-02 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
IL325123A (en) 2018-12-14 2026-02-01 Harmony Biosciences Man Inc Treating 22q11.2 Deficiency Syndrome with Cannabidiol
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
EP4725549A3 (en) * 2019-10-13 2026-06-10 FibroBiologics, Inc. Cannabidiol adjuvant therapy for treatment of disc degenerative disease
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
JP2022551730A (ja) 2019-10-14 2022-12-13 パイク セラピューティクス，インコーポレイテッド カンナビジオールの経皮送達
TWI902836B (zh) * 2020-06-29 2025-11-01 美商和諧生物科學管理股份有限公司 以大麻二酚(cannabidiol)治療X染色體脆折症候群
AU2022257344A1 (en) * 2021-04-12 2023-10-26 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
EP4098254A1 (en) * 2021-06-04 2022-12-07 Assistance Publique, Hopitaux De Paris Cannabidiol for use in the treatment of pain resulting from an indoleamine 2,3-dioxygenase-1 (ido1) related disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807639D0 (en) * 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
ES2396976T3 (es) * 2005-05-25 2013-03-01 Calosyn Pharma, Inc Método y composición para tratar osteoartritis
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
DK2376121T4 (da) * 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
WO2010127033A1 (en) * 2009-04-28 2010-11-04 Alltranz Inc. Formulations of cannabidiol and methods of using the same
EP2424568A1 (en) * 2009-04-29 2012-03-07 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
PT2473475T (pt) * 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
EP2864477A4 (en) * 2012-06-26 2016-02-17 Amberdale Entpr Pty Ltd ISOLATION OF STEM CELLS FROM ADIPOSE TISSUE BY ULTRASONIC CAVITATION, AND METHODS OF USE
WO2016011451A1 (en) * 2014-07-18 2016-01-21 Medipath, Inc. Compositions and methods for physiological delivery using cannabidiol
JP2020530857A (ja) * 2017-08-14 2020-10-29 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 経皮カンナビジオールゲルを用いた変形性関節症の治療方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024085581A1 (ko) * 2022-10-17 2024-04-25 (주)인벤티지랩 염증성 질환의 치료 또는 예방을 위한 서방형 주사용 조성물 및 이의 제조 방법

Also Published As

Publication number Publication date
US20200170963A1 (en) 2020-06-04
JP2023109969A (ja) 2023-08-08
BR112020003025A2 (pt) 2020-08-04
CA3072849A1 (en) 2019-02-21
MX2020001768A (es) 2020-12-03
EP3668500A4 (en) 2021-04-28
WO2019034985A1 (en) 2019-02-21
JP7590803B2 (ja) 2024-11-27
JP2020530857A (ja) 2020-10-29
EP3668500A1 (en) 2020-06-24
AU2018318425A1 (en) 2020-02-27
JP2025024068A (ja) 2025-02-19
US20250268843A1 (en) 2025-08-28
US20240148669A1 (en) 2024-05-09
IL301622A (en) 2023-05-01
IL272593A (en) 2020-03-31
US20240189255A1 (en) 2024-06-13
JOP20200031A1 (ar) 2020-02-12
AU2024205778A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
US20250268843A1 (en) Methods of treatment of osteoarthritis with transdermal cannabidiol gel
KR20200055067A (ko) 성인의 초점성 뇌전증의 치료를 위한 합성 경피성 칸나비디올
CN114786660A (zh) 使用mtorc1调节剂的治疗方法
CN108778266A (zh) 包含二高γ亚麻酸（DGLA）的医药组合物和其用途
KR20230031317A (ko) 칸나비디올로의 취약 x 증후군의 치료
KR20230016003A (ko) 칸나비디올을 사용하는 자폐 스펙트럼 장애의 치료
Torok Extended-release formulation of minocycline in the treatment of moderate-to-severe acne vulgaris in patients over the age of 12 years
TR201906742T4 (tr) Tıbbi bir ürün ve tedavi.
KR20240093852A (ko) 중등도 내지 중증의 불안 및/또는 사회적 회피를 갖는 자폐 스펙트럼 장애가 있는 대상체에서의 과민성 치료
JP7837335B2 (ja) 鎮痛効果を誘導するためのジカルボン酸エステル
KR102542842B1 (ko) Pms의 증상을 완화하는 방법
EP2468270A1 (en) (R)-2-(3-fluoro-4-phenylphenyl)propionic acid for use in the treatment of skin diseases
TW202440106A (zh) 用於治療勃起障礙之化合物
EP2727595B1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
KR20190004316A (ko) 에너지 대사를 표적화하는 작용제를 사용한 활성화된 피부 병태의 치료
CN104906501A (zh) 治疗银屑病的中药组分组合物
US20220305076A1 (en) Topical cyclosporine for treating psoriasis and other ailments
Dahal Assessment of the Percutaneous Absorption of ABH PLO Gel Across Porcine Ear Skin
US20100168254A1 (en) Hydrogel composition for the treatment of dermatological disorders
Agent For topical use only (Not for ophthalmic use)
EP4098254A1 (en) Cannabidiol for use in the treatment of pain resulting from an indoleamine 2,3-dioxygenase-1 (ido1) related disease
JP2014169247A (ja) 経皮吸収用医薬組成物
CN108883056A (zh) 用于治疗外周关节、脊柱关节和/或结缔组织的细胞外基质元件的制剂、制造方法和用途
HK1263116A1 (en) Formulation for treatment of peripheral joints, spinal joints and/or extracellular matrix elements of connective tissue, method of manufacture and uses
OA16802A (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000